[Th17-mediated relapsing-remitting multiple sclerosis is nonresponsive to interferon-β1b]

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Context:

• Relapsing-remitting multiple sclerosis (RRMS) is a chronic autoimmune disease affecting the central nervous system.
• Interferon beta-1b (IFN-β-1b) is a common treatment for RRMS, but its efficacy varies among patients.
• T helper 17 (Th17) cells play a significant role in autoimmune inflammation.

Purpose:

• To investigate the correlation between Th17 cell levels in peripheral blood and the clinical efficacy of IFN-β-1b in RRMS patients.
• To determine if Th17 cell-mediated inflammation predicts treatment response to IFN-β-1b.

Summary:

• Eleven RRMS patients received 250 μg IFN-β-1b for six months.
• Clinical outcomes (EDSS scores) and MRI lesion load were assessed.
• Peripheral Th17 cell counts were measured before treatment.
• Patients were categorized into effective and ineffective treatment groups based on EDSS scores.
• The ineffective group exhibited significantly higher Th17 cell counts pre-treatment compared to the effective group.
• No significant differences in EDSS or lesion load were observed between groups pre-treatment.
• Post-treatment, the effective group showed significant reductions in EDSS scores and lesion load.

Impact:

• Identifies Th17 cell levels as a potential biomarker for predicting IFN-β-1b treatment response in RRMS.
• Suggests that Th17-high RRMS may be refractory to IFN-β-1b therapy.
• Highlights the need for personalized treatment approaches in RRMS based on immune cell profiles.